South Korea has cleared the way to recycle the roughly 30 tons of body fat removed through liposuction each year, converting medical waste that clinics once incinerated into raw material for regenerative medicine.
The change hands biotech companies a domestic supply of stem cells, collagen, and structural tissue, opening a market that Korean lawmakers call a world first.
"The significance of this amendment lies in the fact that it establishes what is believed to be the world's first legal foundation for the medical reuse of discarded fat tissue from living human bodies," she said.
The National Assembly amended the Waste Control Act in June 2026, passing the revision 239 to one with 11 abstentions.
The revision adds human fat tissue alongside the placenta as the only human-derived materials that clinics may recycle rather than burn.
Korea already turns recovered placenta into cosmetics and medicines, and the amendment extends that precedent to fat for the first time.
Manufacturers extract the placenta into a liquid that goes into anti-aging creams, serums, and sheet masks sold across Korean beauty counters.
The same extract feeds prescription drugs such as Laennec, a placenta medicine that Korean regulators cleared to treat liver disease and menopause symptoms.
Human fat carries stem cells, collagen, and extracellular matrix, the scaffold that supports cells and holds tissue together.
Representatives Seo Myung-ok and Kim Wi-sang of the People Power Party proposed the measure, which Seo calls the world's first legal basis for reusing fat from living human bodies.
The law takes effect one year after promulgation, giving the Ministry of Food and Drug Safety and the Ministry of Health and Welfare time to write safety and ethics rules.
Clinics across the country generate about 30 tons of discarded fat each year, and providers have incinerated every gram of it.
365mc, the country's largest liposuction provider, plans to route that tissue to its subsidiary Monicell for stem cell and matrix research.
Kim Nam-cheol, chief executive of 365mc, has tied the effort to a research partnership with the Daegu-Gyeongbuk Medical Complex.
Lee Seung-kyu, vice president of the Korea Bio Association, has framed the discarded tissue as an untapped domestic resource for the biotech sector.
Uses for the recovered tissue span wound dressings, burn treatment, dermal fillers, cell culture media, and diagnostic kits.
Established biotech firms moved within days of the vote.
L&C Bio plans to launch a fat-based product called Mega Adipo next year, drawing on research it began in 2018 and patents it registered in Korea and China.
Hans Biomed will expand its own matrix-based skin booster line on the same timeline.
The revision converts a disposal cost into a product pipeline.
The domestic skin booster market built on extracellular matrices could climb from 9.9 billion won in 2025 to 172.9 billion won by 2027.
Companies with matrix products already on shelves stand to gain first.
L&C Bio's Rituo brought in about eight billion won during the first quarter of 2026, topping its full 2025 total.
Hans Biomed's Celldm earned 3.7 billion won in the same quarter, with the firm projecting 30 billion won for the year.
The United States shows where the market can lead, as MTF Biologics already sells a fat-derived filler called Renuva into a market worth tens of billions of won.
Regulators abroad increasingly favor reusing medical materials rather than destroying them.
The European Union will propose a Circular Economy Act in the third quarter of 2026 to unify fragmented waste rules across the bloc.
MedTech Europe and 65 other industry groups have urged negotiators to let the healthcare sector reuse more material under common rules.
Recycling fat also trims the emissions and cost that come with burning biological waste in hospital furnaces.
A UK hospital study found that high-temperature incineration releases about 1,074 kilograms of carbon dioxide per ton of waste, while recycling drops that figure below 65 kilograms.
Whether other countries adopt the approach depends on how Korea's drug and health ministries write the safety rules over the coming year.
